Author: fkrupps

WALTHAM, Mass. – November 13, 2025 – Danforth Health, Inc. today announced an expansion of its Market Access & Value practice with the addition of Beth Ann Bender, a seasoned expert in payer insights and stakeholder engagement. Bender brings over 25 years of experience in healthcare market research and is the founder of FieldQuest, whose curated payer panel will allow Danforth Health clients to capture rapid, high-quality insights that inform access and reimbursement strategy from early development through launch.

Bender will lead efforts to deepen payer insight capabilities across the commercialization lifecycle. Her proprietary approach and long-standing relationships with health plan and hospital system stakeholders will strengthen Danforth Health’s ability to generate fast, reliable input from the people who influence drug coverage and reimbursement decisions.

At the core of this expanded capability is the integration of the FieldQuest payer panel – a trusted network of healthcare decision-makers who determine what treatments and therapies are covered by insurance plans. Engaging this panel will allow life science companies to test ideas, validate assumptions, and hear directly from real-world experts who shape access for patients.

“Beth Ann’s experience and network accelerate our ability to deliver meaningful payer insights to clients preparing for launch and beyond,” said Scotty Bowman, Managing Director, Danforth Health Market Access & Value. “By integrating FieldQuest’s curated payer panel and insights with our current strategy, evidence, and pricing and reimbursement services, we can move even faster from insight to action for clients preparing to launch or grow their brands.”

“Joining Danforth allows me to bring the FieldQuest model to a broader stage,” said Bender. “I’ve always believed that better access begins with better insight. Now, we can combine real-time payer feedback with the strategic and operational muscle needed to turn that feedback into smarter decisions and stronger patient access.”

About Danforth Health

Danforth Health is a unified platform purpose-built to empower life science innovation. By integrating the capabilities of best-in-class affiliates, Danforth Health provides tailored, cross-functional support across finance and human resources, investor and public relations, discovery and development, regulatory and clinical, commercial and marketing, market research and analytics, and market access and value. The model is built for flexibility, scalability, and impact – serving life science companies at any stage and helping them move faster, smarter, and more efficiently to achieve transformative outcomes for patients. Headquartered in Waltham, Massachusetts, Danforth Health has partnered with more than 1,800 life science companies around the world. Learn more at www.danforthhealth.com.

WALTHAM, Mass. – October 22, 2025 – Danforth Health, Inc. today announced the acquisition of Asymmetry Group, LLC, strengthening its ability to help scientific innovation reach market and achieve impact for patients.

The acquisition brings 30 seasoned experts in the areas of corporate advisory and commercial strategy, launch planning and execution, and organizational capability building – enhancing the depth and flexibility of Danforth Health’s Commercial & Marketing practice. Founder and Managing Director Greg Lief and Managing Director Yakir Siegal will continue to lead the Asymmetry team.

“Advancing a therapy from development to market requires not only scientific and regulatory achievement, but also early, strategic alignment around commercial goals,” said Chris Connors, CEO of Danforth Health. “Asymmetry Group brings deep expertise in helping companies prepare for and execute successful launches. The team’s insight and experience strengthen our ability to guide clients through one of the most pivotal phases of their journey – delivering innovation to patients.”

“Joining Danforth Health allows us to bring even greater value to healthcare innovators through an integrated model that aligns commercialization strategy with the full spectrum of development, regulatory, financial, and communications expertise,” said Greg Lief. “Together, we can help life science leaders deliver meaningful innovation with a powerful continuum of support – from early planning and organizational design to brand development, launch execution, and sustained market growth.”

Founded in 2017, Asymmetry Group has built a strong reputation for helping emerging and established life science organizations build, launch, and scale effectively. Its team brings proven experience across corporate strategy, asset commercialization strategy, go-to-market strategy, innovative product launch planning and execution, commercial operations, and organizational capability building – supporting clients as they navigate the complexities of market entry and growth. As part of Danforth Health, these capabilities are available alongside development, clinical, regulatory, and business support for a fully connected solution at every stage of the corporate lifecycle.

This latest acquisition advances Danforth Health’s strategy to build an integrated platform of specialized affiliates – including Danforth Advisors, Advyzom, Argot Partners, Benchworks, Elite BioPharma Consulting, PharmaDirections, and VPMR. The platform is backed by Avesi Partners and united in the mission to empower life science innovation.

About Asymmetry Group
Asymmetry Group enables breakthrough impact in the healthcare industry through partnership with extraordinary organizations at the forefront of healthcare innovation. Asymmetry achieves this goal by working at the intersection of strategy and operations, providing comprehensive support to commercialize innovation and manage large-scale, complex organizational transformations. The firm executes traditional corporate and commercial strategy consulting projects such as portfolio strategy, product strategy and corporate advisory work. Asymmetry also executes complex strategic initiatives such as supporting new product launches, serving as the voice of commercial, and embedding deep cross-functional capabilities. For more information, visit www.asymmetrygroup.com. 

About Danforth Health
Danforth Health is a unified platform purpose-built to empower life science innovation. By integrating the capabilities of best-in-class affiliates, Danforth Health provides tailored, cross-functional support across finance and human resources, investor and public relations, discovery and development, regulatory and clinical, commercial and marketing, market research and analytics, and market access and value. The model is built for flexibility, scalability, and impact—serving life science companies at any stage and helping them move faster, smarter, and more efficiently to bring innovation to patients. Headquartered in Waltham, Massachusetts, Danforth Health has partnered with more than 1,800 life science companies worldwide. Additional information is available at www.danforthhealth.com.

Integrated platform helps life science companies move from discovery to commercialization with greater efficiency and impact

WALTHAM, Mass. – September 10, 2025 – Danforth Global, Inc. today announced the launch of Danforth Health, a unified platform built to empower life science innovation. By delivering integrated, cross-functional expertise at every stage – from discovery through commercialization – the platform reduces risk, streamlines execution, and maximizes the potential of scientific breakthroughs to reach patients with efficiency and impact.

Danforth Health unites its affiliated entities under a shared identity and purpose, coordinating services across finance and human resources, regulatory and clinical, investor and public relations, commercial and marketing, market research and analytics, and market access and value. This connected model gives companies one adaptable partner to help them advance through critical milestones – whether entering the clinic, preparing for IPO, or executing on commercial strategy.

Chris Connors, CEO of Danforth Advisors, will serve as CEO of Danforth Health, guiding strategy across all affiliated entities.

“Advancing new therapies from discovery to market requires not only the achievement of critical development and regulatory milestones, but also a strong business foundation, effective storytelling, and early attention to commercial strategy,” said Connors. “Danforth Health was built to provide that full balance – combining strategic guidance and hands-on execution across disciplines so companies can focus on what matters most: the innovation.”

Danforth Health was built both organically and through strategic acquisitions, beginning with the founding of Danforth Advisors in 2011 and fueled by investment from Avesi Partners. Today it also comprises the expertise and services of Advyzom, Argot Partners, Benchworks, Elite BioPharma Consulting, PharmaDirections, and VPMR —trusted partners to companies across the life science ecosystem.

About Danforth Health
Danforth Health is a unified platform purpose-built to empower life science innovation. By integrating the capabilities of best-in-class affiliates, Danforth Health provides tailored, cross-functional support across finance and human resources, regulatory and clinical, investor and public relations, commercial and marketing, market research and analytics, and market access and value. The model is built for flexibility, scalability, and impact — serving life science companies at any stage and helping them move faster, smarter, and more efficiently to achieve transformative outcomes for patients. Headquartered in Waltham, Massachusetts, Danforth Health has partnered with more than 1,800 life science companies around the world. Additional information is available at www.danforthhealth.com.